Biotech Daily

Tuesday October 27, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: ALCIDION UP 10%; LUMOS DOWN 24%**

*** NATURAL MEDTECH WANTS $2m FOR PSILOCYBIN, MDMA PRODUCTION**

*** RESONANCE 'MRI DETECTS LIVER FIBROSIS'; GLP-1; $6m PLACEMENT**

*** BOTANIX Q1 RECEIPTS, ROYALTIES UP 78% TO $16m**

*** IMMURON Q1 SALES UP 9% TO $2.2m**

*** ONCOSIL: 'PANCREATIC CANCER DEVICE 100% DISEASE CONTROL'**

*** WEHI: 'SMCHD1 PROTEIN REMOVAL FOR PRADER-WILLI SYNDROME'**

*** ADELAIDE UNI: 'SQUID BARE LOOPS MAY IMPROVE MEDICAL DEVICES'**

*** PAINCHEK UK HALLMARK CARE HOME PAIN APPLICATION DEAL**

*** ARGENT LICENCES 4 MARIJUANA GENOTYPES**

*** CLARITY DOSES PHASE III CU-64 SAR-BIS-PSMA TRIAL**

*** AROVELLA DOSES 1st PHASE I ALA-101 BLOOD CANCER PATIENT**

*** RADIOPHARM TAKES $8m ROCKFORD RDTI LOAN**

*** ALCIDION 135m SHARE BUY-BACK**

*** TRIVARX POTENTIAL 2nd STRIKE, 15m BOARD OPTIONS AGM**

*** HYDRIX 42m CHAIR GAVIN COOTE RIGHTS AGM**

*** RHYTHM 3.5m BOARD OPTIONS AGM**

*** NEURIZON 1.5m DIRECTOR OPTIONS AGM**

*** MEMPHASYS 10-TO-1 CONSOLIDATION AGM**

*** NOXOPHARM REQUESTS 'CAPITAL RAISING' TRADING HALT**

*** IMPEDIMED APPOINTS DR NICOLE STOUT CLINICAL INNOVATION HEAD**

*** SUBARAJ SUBRAMANIAM REPLACES AVECHO CFO MELANIE LEYDIN**

MARKET REPORT

The Australian stock market was up 0.46 percent on Tuesday October 27, 2026, with the ASX200 up 40.2 points to 8,850.1 points. Fifteen of the Biotech Daily Top 40 companies were up, 18 fell, five traded unchanged and two were untraded.

Alcidion was the best, up 1.0 cent or 10 percent to 11 cents, with 3.2 million shares traded. Orthocell climbed 8.1 percent; Micro-X was up 7.3 percent; Nova Eye rose 6.7 percent; Artrya and Prescient were up more than five percent; Mesoblast and Polynovo improved three percent or more; Clinuvel, Imugene and Medical Developments rose two percent or more; Amplia and Emvision were up more than one percent; with CSL, Nanosonics and Neuren up by less than one percent.

Lumos led the falls, down 2.0 cents or 23.8 percent to 6.4 cents, with 16.55 million shares traded. Botanix lost 15.4 percent; Optiscan and Resonance were down more than nine percent; EBR was down 7.4 percent; Racura and Starpharma shed more than six percent; Curvebeam and Syntara were down five percent or more; Actinogen, Immutep and Proteomics fell more than four percent; 4D Medical and Imricor shed more than two percent; Aroa, Avita, Clarity, Cochlear, Pro Medicus and Resmed were down one percent or more; with Telix down by 0.5 percent.

NATURAL MEDTECH PTY LTD

Natural Medtech chief executive officer Luke McFarlane hopes to raise $2 million to produce 3,4 methylene-dioxy-meth-amphetamine and psilocybin from sugar and yeast.
A co-founder of the Sydney-based company with chief operating officer Mark Hestermann, Mr McFarlane said Natural Medtech was selling 3,4 methylene-dioxy-meth-amphetamine (MDMA) and psilocybin to universities, including the Australian National University, Monash University and several unnamed companies.
According to the company's website, it was founded in 2021 and holds Australian Therapeutic Goods Administration schedule B and schedule 9 licences for clinical good manufacturing practice and is "the only psilocybin and MDMA active pharmaceutical ingredient manufacturer in Australia".
Natural Medtech said it supplied more than 10 phase II or later trials and the "sustainable process [uses] no petro-chemicals, no harsh industrial solvent [and has] no plastic waste".
According to the website "bio-synthesis is how nature makes its most complicated molecules … we engineer biology to manufacture active pharmaceutical ingredients".
Mr McFarlane told Biotech Daily that the technology was invented with the University of Western Australia and Natural Medtech held all the intellectual property.
Mr McFarlane said the $2 million raise would go to bio-synthetic manufacturing capability, expand the product set, and increase staff; and the company was "the partner of choice for local authorized prescribers and clinical researchers".
Mr McFarlane said that apart from psilocybin and MDMA the yeast and sugar bio-synthesis process is used for manufacturing psilocin, di-methyl-tryptamine (DMT) and lysergic acid diethylamide (LSD).
Mr McFarlane said the funds raised would be in unsecured convertible notes at 12.0 percent a year for 24 months, converting on raising $2 million or more or an initial public offer or sale of the company, valuing the company at about $40 million.
Interested investors should contact Mr McFarlane by telephone on: +61 414 194 067 or by email at luke.mcfarlane@naturalmedtech.com.
Natural Medtech is a private company.

RESONANCE HEALTH

Resonance says preliminary results from 50 of 68 patients show its non-invasive MRI software can detect advanced liver fibrosis and it will raise $6 million in a placement.

Resonance said its Fibrosis Assessment system aimed to measure fibrosis in the liver using MRI sequences without expensive hardware or invasive contrast injections.

The company said that liver fibrosis was a key biomarker endpoint in glucagon-like peptide-1 (GLP-1), metabolic disease and obesity clinical trials.

In 2022, Resonance said it filed a provisional Australian patent to protect “an invention for the detection and assessment of fibrosis in the liver and potentially other organs” using non-invasive magnetic resonance imaging (MRI) (BD: Dec 21, 2022).

At the time, the company said that a 30-subject initial proof of concept study had found “a strong capability to predict the absolute presence of liver fibrosis” with MRI.

Today, the company said the extended proof-of-concept study of its Fibrosis Assessment, against liver biopsy, showed that Fibrosis Assessment accuracy was “in line with the widely used Fibroscan ultrasound device for significant fibrosis”; and its software had 80.0 percent specificity and 75.0 percent sensitivity for significant fibrosis, and 93.5 percent specificity and 57.9 percent sensitivity for advanced fibrosis.

The company said its extended proof-of-concept study was conducted at sites in Malaysia, China and India, with the preliminary results from 50 subjects in China.

Resonance said the subjects were recruited in China with a spectrum of clinical conditions including liver cancer and the preliminary data was “a strong baseline and bona fide proof-of-concept which suggests that the Fibrosis Assessment [software-as-a-medical-device] product can detect significant, advanced liver fibrosis”.

The company said unlike magnetic resonance elastography (MRE) and Fibroscan its device required “no additional hardware or software at the imaging site”.

Resonance said the device analyzed standard MRI sequences generated images on existing scanners and was delivered through its core laboratory.

Separately, the company said it had “firm commitments” to raise $6.0 million at 7.2 cents a share in an ‘oversubscribed’ placement to fund MRI endpoint acceleration, Trialswest network expansion, its non-invasive liver fibrosis device and working capital.

Resonance said the issue price was a 6.4 percent discount to the five-day volume-weighted average price and a 12.2 percent discount to the last closing price.

The company said it expected 2026-’27 revenue of $17 million to $22 million and earnings before interest, taxation, depreciation and amortization (Ebitda) of $2.6 million to $3.6 million, excluding any revenues that may accrue from the non-invasive liver fibrosis device, acquisitions, additional Trialswest sites and expansion.

Resonance said Bell Potter Securities was lead manager to the placement.

Resonance managing-director Andrew Harrison said the preliminary results were “a very encouraging step towards commercializing the Fibrosis Assessment device in GLP-1 clinical trials”.

“Importantly, we now have a baseline to improve the model accuracy using data we already hold, without another trial,” Mr Harrison said.

“With GLP-1 and metabolic trials already scanning the liver, a fibrosis bio-marker from standard MRI with no added hardware opens a real opportunity with sponsors, and taking [software-as-medical-devices] from development through to regulatory clearance is what Resonance has done for 20 years,” Mr Harrison said.

“An ‘oversubscribed’ placement is a clear endorsement of our strategy and another step in building an institutional register, with the research coverage and liquidity that brings,” Mr Harrison said.

Resonance fell 0.8 cents or 9.8 percent to 7.4 cents with 7.1 million shares traded.

BOTANIX PHARMACEUTICALS

Botanix says customer receipts and royalties for the three months to September 30, 2026 rose 77.8 percent to $15,601,000, compared to the prior corresponding period.
Botanix said prescriptions of its Sofdra for excessive sweating for the three months were 35,130, “affirming the resized sales force’s ability to continue Sofdra growth”.
In 2024, the company said the US Food and Drug Administration had approved Sofdra, or sofpironium bromide topical gel, for excessive underarm sweating in adults and children aged nine years and older (BD: Jun 20, 2024).
Today, Botanix said it had a $9,225,000 three-month cash burn, with cash and equivalents of $24,358,000 at September 30, 2026 compared to $49,246,000 at September 30, 2025.
Botanix fell 0.2 cents or 15.4 percent to 1.1 cents with 41.5 million shares traded.

IMMURON

Immuron says Travelan sales for the three months to September 30, 2026 rose nine percent to $2.2 million, compared to the prior corresponding period.
Immuron said the increase in sales of Travelan for traveler’s diarrhoea was due to the brand re-launch, new packaging and brand communications which “resonated strongly with consumers” and was well received and supported by major pharmacy groups.
The company said that US sales fell 19 percent for the three months to $300,000 due to “customs and logistics challenges delaying replenishment of US inventory”, Canada sales rose 286 percent to $100,000 and Australia sales were up 14 percent to $1.8 million.
Immuron fell 0.3 cents or 7.5 percent to 3.7 cents.

ONCOSIL MEDICAL

Oncosil says a 17-patient study shows its pancreatic cancer device had 100 percent local disease control, with seven partial responses and nine stable disease patients.
Oncosil said the prospective, single-centre, observational study was conducted at Athens, Greece’s Agios Savvas Hospital and included 17 consecutive, highly selected patients with unresectable locally advanced pancreatic cancer treated with its radio-therapy device in addition to gemcitabine and nab-paclitaxel chemotherapy.
The company said 16 patients reported local disease control at 16 weeks, with four patients achieving clear-margin resections following treatment.
Oncosil said 13 of 16 evaluable patients had a cancer antigen (CA)19-9 tumor marker reduction of at least 50 percent, with a median reduction of 73.7 percent at 16 weeks, with a 21.4 percent median reduction in tumor diameter at 16 weeks.
The company said there were “predominately grade one-to-two adverse events, with one grade three abdominal pain event and no grade four-to-five adverse events”.
Oncosil said estimated median overall survival was 20.0 months, from chemotherapy initiation and there were “only three deaths during a median overall survival follow-up of 15.6 months”, with survival estimates “exploratory and statistically immature”.
Oncosil said the study, titled ‘Early Local Tumour Control and Feasibility of Intratumoral P-32 Microparticle Implantation in Patients with Locally Advanced Pancreatic Cancer: A Prospective Single-Center Observational Cohort Study’ was published in the journal Cancers, with the full article available at: https://www.mdpi.com/2072-6694/18/20/3331.
Oncosil managing-director Nigel Lange said while the results were “from a small patient cohort, they provide further clinical experience on the use of Oncosil in addition to chemotherapy as part of a multi-disciplinary treatment approach”.
Oncosil was up five cents or 7.1 percent to 75 cents.

WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Walter and Eliza Hall Institute says removing the SMCHD1 protein "releases a genetic 'brake' that silences healthy genes in Prader-Willi syndrome".
WEHI said Prader-Willi syndrome affected the brain, causing lifelong physical and developmental issues, and the discovery could help treat the underlying cause.
The Institute said therapeutic development would be progressed through a Melbourne-based spin-out biotechnology company called Togglelux Therapeutics.
WEHI said a world-first study restored gene activity in patient-derived cells and animals without causing problems elsewhere in the body by removing the 'structural maintenance of chromosomes flexible hinge domain-containing protein 1' (SMCHD1).
The Institute said the protein was discovered at WEHI in 2008, helped regulate gene activity and "in Prader-Willi syndrome switched off certain genes essential for development and brain function, contributing to symptoms like developmental delays, intellectual disability and an insatiable appetite that can lead to obesity".
WEHI said patients often relied "on multiple medications, surgeries and specialist care, but these treatments address symptoms rather than the cause, providing limited relief".
The Institute said researchers combined clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing, stem-cell and genomic technologies "to track what happened when SMCHD1 was removed, measuring the effects across thousands of genes and in the most disease-relevant brain tissue".
WEHI said the study, titled 'SMCHD1 is a target for gene-activation therapy to treat Prader-Willi syndrome' was published in Science Advances at: https://bit.ly/47GO52s.
The Institute's epigenetics laboratory deputy director Prof Marnie Blewitt said "we now have the strongest evidence that removing SMCHD1 can restore gene activity lost in Prader-Willi syndrome without disrupting the rest of the body".

ADELAIDE UNIVERSITY

Adelaide University says it has found 'bare loops' improve superconducting quantum interference devices, or Squids, which may improve medical diagnostics.
Adelaide University said the research solved a problem that limited the performance of Squids, "some of the world's most sensitive sensors of electromagnetic fields" used in brain imaging systems, scientific instruments and advanced radio-frequency sensors.
The University said Squids could "detect incredibly small changes in magnetic fields … [but] have struggled to accurately identify when a magnetic field is exactly zero".
Adelaide University said engineers had addressed this problem by building complex circuits containing hundreds or even thousands of differently sized superconducting loops, which reduced the overall sensitivity of the device.
The University said it found "a simpler solution, instead of making loops different sizes, the researchers kept them the same size but strategically replaced some with 'bare loops' that contain no Josephson junctions, a key component of traditional Squid devices".
Adelaide University said the research, titled 'Synthetic areas spread in two-dimensional Superconducting Quantum Interference Filter Arrays' was published in the journal Physical Review Applied, available at: https://doi.org/10.1103/wc1k-wxtc.
The University said the 'bare loops' changed "how magnetic signals move through the circuit, creating what the researchers call a 'synthetic area spread'".
Adelaide University said potential future applications included "improved brain monitoring systems, more sensitive radio-frequency receivers, low-noise communication technologies and advanced electromagnetic sensing platforms".
The University said further testing was required before commercialization.

PAINCHEK

Painchek says it has a contract for 1,800 licences for its pain monitoring smartphone application with Essex, England's Hallmark Luxury Care Homes.
Painchek said its software would be introduced at 23 Hallmark Luxury Care Homes locations across England and Wales.
The company said at June 30, it had 90,198 licences, generating $4.46 million in annual recurring revenue (ARR), with 33,470 licences and $1.85 million in ARR in the UK.
Biotech Daily calculates that the Hallmark contract was worth about $99,500 a year.
Painchek said implementation was expected to begin in late January 2027, with a near-term priority "to deliver implementation and training, support adoption within day-to-day care and establish ongoing use across the contracted portfolio".
Painchek fell 0.3 cents or 4.1 percent to seven cents.

ARGENT BIOPHARMA (MGC PHARMACEUTICALS)

Argent says it has signed a 10-year licence for Bangkok's Thai Phytomed International Co Ltd to develop four of its marijuana genotypes.
Argent said it would receive a royalty equal to 15 percent of profits generated from the commercialization of the licenced genetics, calculated three-monthly.
The company said it would terminate the licence if no commercial sale of licenced products was made within 24 months after delivery of the licenced genetic material.
Argent said Thai Phytomed would have "exclusive worldwide rights to commercially cultivate, propagate, process, extract, manufacture, market, distribute, sell, import and export the licenced genetics and products derived from them, including flower, extracts and cannabinoid active pharmaceutical ingredients, subject to applicable regulatory requirements".
Argent said the licence had an initial 10-year term and could be renewed for 10 more years and the four genotypes were MXC-THC-10/3, MXC-THC-81/5, MXC-THC-40/3 and MXC-THC-40/2.
Argent fell 0.4 cents or 13.8 percent to 2.5 cents.

CLARITY PHARMACEUTICALS

Clarity says it has dosed its 383-patient, phase III trial of copper-64 Sar-Bis-prostate specific membrane antigen (PSMA) for imaging prostate cancer prior to prostatectomy.
In 2023, Clarity said it dosed the first of up-to 383 patients in its 'Clarify' phase III trial of copper-64 Sar-Bis-PSMA for pre-prostatectomy prostate cancer (BD: Dec 22, 2023).
Today, the company said the trial was being conducted at sites in the US and Australia, with primary endpoints of sensitivity and specificity for detecting prostate cancer within the pelvic lymph nodes compared to the standard of truth, assessed independently at day one and day two.
Clarity said top-line data was expected by July 2027, along with top-line results from its 220-patient, phase III, 'Amplify' trial of copper-64 Sar-Bis-PSMA for biochemical recurrence of prostate cancer.
The company said the study results were intended to provide sufficient evidence to support an application to the US Food and Drug Administration for approval of copper-64 Sar-Bis-PSMA as a diagnostic imaging agent in prostate cancer patients.
Clarity executive chair Dr Alan Taylor said the milestone was "a significant achievement from our team and collaborators".
Clarity fell 2.5 cents or 1.6 percent to $1.55 with 4.9 million shares traded.

AROVELLA THERAPEUTICS

Arovella says it has dosed the first patient in its phase I trial of ALA-101 for non-Hodgkin lymphoma and leukaemia blood cancers.
In June, Arovella said it had approval for a first-in-human, trial of ALA-101 chimeric antigen receptor (CAR) invariant natural killer (INK) T-cell for patients with relapsed or refractory lymphomas and leukaemia at Melbourne's Alfred Hospital (BD: Jun 25, 2026).
Today, the company said the patient received ALA-101 following standard lympho-depleting chemotherapy at the Alfred Hospital.
Arovella was up 0.1 cents or two percent to five cents.

RADIOPHARM THERANOSTICS

Radiopharm says it has an $8,000,000 loan from Perth's Rockford Capital secured against its expected Federal Government Research and Development Tax Incentive.
Radiopharm said the loan included "interest charged at a commercial rate" and was repayable on receipt of its expected tax incentive for eligible research and development expenditure to June 30, 2027, due by October 26, 2027.
The company said the funds would be used for clinical trials and working capital.
Radiopharm fell 0.1 cents or 20 percent to 0.4 cents with 18.0 million shares traded.

ALCIDION GROUP

Alcidion says it will conduct an on-market buy-back of up-to 10 percent of the shares on issue over the next 12 months, equal to about 134,980,515 shares.
Alcidion said the buy-back was expected to begin on November 10, 2026 and was part of its "broader capital allocation framework as the company continues to strengthen its financial profile, improve profitability and generate cash".
The company said it had cash reserves of $20.6 million at June 30, 2026.
Alcidion was up one cent or 10 percent to 11 cents with 3.2 million shares traded.

TRIVARX (FORMERLY MEDIBIO)

Trivarx says investors will vote on a potential remuneration report second strike and a conditional board spill and the issue of 15,000,000 options to its board.
Last year, Trivarx said its annual general meeting passed all resolutions with 33.16 percent voting a remuneration report first strike (BD: Nov 21, 2025).
Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 a company with a vote of 25 percent or more against the remuneration report in two successive annual meetings must vote on a board spill.
Today, the company said its annual general meeting would vote to issue chair David Trimboli, executive director Dr Tony Keating and director Chris Ntoumenopoulos 5,000,000 options, each, exercisable at three cents each within three years.
Trivarx said the options were in addition to Mr Trimboli, Dr Keating and Mr Ntoumenopoulos' $134,850 yearly fees.
The company said shareholders would vote to adopt the remuneration report, re-elect Anthony Keating as a director, approve the placement capacity and employee incentive plan as well as issue shares in lieu of directors' fees.
The meeting will be held at the Treasury, Ground Floor, 1 Cathedral Avenue, Perth on November 26, 2026 at 9am (AWST).
Trivarx was unchanged at 0.8 cents with 1.4 million shares traded.

HYDRIX

Hydrix says its annual general meeting will vote to issue chair Gavin Coote 42,000,000 long-term incentive performance rights, valued at 50 percent of his $336,000 yearly pay.
Hydrix said investors would vote to adopt the remuneration report, re-elect director Paul Wright, ratify the issue of securities under its convertible note offer and the issue of securities to related parties and approve the 10 percent placement capacity.
The meeting will be held at Thomsons, Level 23, 525 Collins Street, Melbourne on November 26, 2026 at 3pm (AEDT).
Hydrix was untraded at 0.25 cents.

RHYTHM BIOSCIENCES

Rhythm says its annual general meeting will vote to issue 3,496,892 options to managing-director Dr David Atkins and directors Maureen Baker and Carl Stubbings.
Rhythm said shareholders would vote to issue Dr Atkins 1,006,374 options, exercisable at 20 cents each by July 21, 2030 and Ms Baker and Mr Stubbings 1,245,259 options, each, exercisable at 20 cents each by November 24, 2030.
The company said the options were in addition to Dr Atkins' $562,605 annual pay and Ms Baker and Mr Stubbings' $52,500 yearly fees.
Rhythm said investors would vote to adopt the remuneration report, elect Sue MacLeman, Ms Baker and Mr Stubbings as directors, approve the 10 percent placement capacity, adopt the employee incentive omnibus plan, ratify the prior issue of underwriter options, and issue Dr Atkins deferred shares.
The meeting will be held online and at K&L Gates, Rialto South Tower, Level 25, 525 Collins Street, Melbourne on November 24, 2026 at 11am (AEDT).
Rhythm was untraded at 6.5 cents.

NEURIZON THERAPEUTICS

Neurizon says its annual general meeting will vote to issue 1,500,000 options to director Dr Ross Murdoch, exercisable at 12 cents each by June 30, 2029.
Neurizon said the options were in addition to Dr Murdoch's $90,000 yearly cash fees.
The company said investors would vote to adopt the remuneration report, elect Dr Murdoch as a director, approve the issue of convertible notes to Obsidian Global and approve the 10 percent placement capacity.
The meeting will be held at
Neurizon fell 0.2 cents or 2.3 percent to 8.6 cents.

MEMPHASYS

Memphasys says its annual general meeting will vote to approve a 10-to-one share consolidation and following the consolidation would have 309,523,374 shares on issue.
Memphasys said, if approved, the consolidation had a record date of November 30 and an effective date of November 25, 2026.
The company said investors would vote to adopt the remuneration report, elect David Tasker, Melissa Peters and Marjan Mikel as directors, renew the employee share option plan and approve the 10 percent placement facility.
The meeting will be held online on November 25, 2026 at 2pm (AEDT).
Memphasys was unchanged at 0.4 cents.

NOXOPHARM

Noxopharm has requested a trading halt “pending an announcement by the company to the market regarding a material capital raising”.
Trading will resume on October 29, 2026, or on an earlier announcement.
Noxopharm last traded at 5.2 cents.

IMPEDIMED

Impedimed says it has appointed Dr Nicole Stout as chief clinical innovation officer, effective from November 1, 2026, to lead clinical strategy, research and affairs.
Impedimed said Dr Stout had more than 25 years of experience in identifying treatment-related complications in oncology and was American Cancer Society senior director of survivorship and worked at West Virginia University Cancer Institute and the US National Institute of Health Clinical Center.
The company said Dr Stout would guide clinical strategies to help health systems adopt its Sozo bio-impedance spectroscopy digital health platform in oncology.
Impedimed was unchanged at 0.4 cents with 23.15 million shares traded.

AVECHO BIOTECHNOLOGY

Avecho says it has appointed Subaraj Subramaniam as its chief financial officer, replacing Melanie Leydin who has served since 2018.
Avecho said Mr Subramaniam had more than 15 years of experience in accounting, including seven years supporting ASX-listed companies and was a senior manager at financial services company Vistra Australia.
Avecho was unchanged at 1.4 cents with 1.9 million shares traded.